{"success":true,"data":{"pressRelease":{"id":"115916","rtpr_id":"nGNX1lYNCD","ticker":"STXS","exchange":"NYSE American","all_tickers":["STXS"],"title":"Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates","author":"Globe Newswire","published_at":"2026-08-11T20:01:00.110Z","article_body":"* Robotic catheter revenue surpasses $1M in the quarter, growing 270%\nsequentially\n* First GenesisX robotic system purchase by US hospital to be installed this\nfall\n* Multiple Synchrony digital operating room systems sold and installed\nfollowing FDA clearance in April\n* Completed previously announced acquisition of Robocath, strengthening\nrobotic technology leadership across the full spectrum of endovascular\nprocedures\nST. LOUIS, Mo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stereotaxis\n(https://www.globenewswire.com/Tracker?data=gcMmZUXDGD1yUqVYZTVnNNZHfPAG_2Kaa_we2f8BLBbjgB0UWZYBVBS2UHTTqbmuC8yZkbDPHnBIRFfNodUWgqQ_ZSVCLHlAGqESf1jY-mY=)\n(NYSE: STXS), a pioneer and global leader in surgical robotics for minimally\ninvasive endovascular intervention, today reported business updates and\nfinancial results for the second quarter ended June 30, 2026.\n\n“Stereotaxis has reached an important commercial inflection point. Following\nyears of product development and regulatory milestones, the Company’s\nexpanded robotic platform is now generating accelerating commercial adoption\nacross multiple product lines,” said David Fischel, Stereotaxis Chairman and\nCEO. “Over the last several years we advanced an exciting ecosystem of\nrobotic, catheter and digital innovations through development and regulatory\nmilestones. We are now witnessing the initial green shoots of commercial\nsuccess, including quarterly revenue from our novel robotic catheters\nexceeding one million dollars, the first Synchrony system sales, and the first\nUS purchase of a GenesisX robot.”\n\n“We are making methodical progress on the operational and commercial efforts\nneeded to drive revenue growth. We expect continued momentum throughout this\nyear as we ramp manufacturing and address commercial friction. We have line of\nsight to sustained revenue growth and reaching cash flow profitability in the\ncoming quarters.”\n\n“In parallel to our commercial efforts, we continue to invest in a broad\npipeline of innovations that expand our technology into a platform across\nendovascular surgery, enhances our competitiveness in electrophysiology, and\ndelivers digital connectivity, automation and intelligence to the operating\nroom.”\n\n2026 Second Quarter Financial Results\nRevenue for the second quarter of 2026 totaled $7.7 million. System revenue of\n$1.5 million declined from $3.0 million in the prior year second quarter, with\nthe lack of a robotic system delivery in the quarter partially countered by\ninitial Synchrony sales. Recurring revenue of $6.2 million increased from $5.8\nmillion in the prior year second quarter, reflecting contributions from\nStereotaxis’ new robotic catheters counteracting general procedural pressure\nfrom limited catheter supply.\n\nGross margin for the second quarter of 2026 was 58% of revenue. Recurring\nrevenue gross margin was 66%, and system gross margin was 29%. Operating\nexpenses in the quarter of $9.1 million included $2.5 million in non-cash\ncharges for stock compensation expense, mark-to-market adjustment for\nacquisition related contingent earnout consideration, and amortization of\nacquired intangible assets. Excluding these non-cash charges, adjusted\noperating expenses were $6.6 million, consistent with the year-ago period when\nadjusting for a one-time employee retention tax credit received in the prior\nyear.\n\nOperating loss and net loss in the second quarter of 2026 were ($4.6) million\nand ($4.5) million, respectively, compared with ($4.0) million and ($3.8)\nmillion in the previous year. Adjusted operating loss and adjusted net loss\nfor the quarter, excluding non-cash charges, were ($2.1) million and ($2.0)\nmillion, respectively, compared with ($1.4) million and ($1.3) million in the\nprevious year quarter. Negative free cash flow for the second quarter was\n($3.7) million, consistent with the previous year.\n\nCash Balance and Liquidity\nAt June 30, 2026, Stereotaxis had cash and cash equivalents of $10.5 million\nand no debt.\n\nForward Looking Expectations\nStereotaxis anticipates recurring revenue to grow to approximately $7 million\nin the third quarter and $8 million in the fourth quarter of this year, driven\nby methodical increases in MAGiC catheter manufacturing. System revenue is\nexpected to be approximately $3 million in each of the third and fourth\nquarters.\n\nStereotaxis believes it can advance its strategy, integrate Robocath, and grow\nrevenue significantly without having to subject investors to substantial\ndilution. Cash flow profitability is anticipated to be reached in the first\nhalf of 2027.\n\nConference Call and Webcast\nStereotaxis will host a conference call and webcast today, August 11, 2026, at\n4:30 p.m. Eastern Time. To access the conference call, dial 800-715-9871 (US\nand Canada) or 646-307-1963 (International) and give the participant pass code\n4404741. To access the live and replay webcast, please visit the investor\nrelations section of the Stereotaxis website at www.Stereotaxis.com.\n\nAbout Stereotaxis\nStereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical\nrobotics for minimally invasive endovascular intervention. Its mission is the\ndiscovery, development and delivery of robotic systems, instruments, and\ninformation solutions for the interventional laboratory. These innovations\nhelp physicians provide unsurpassed patient care with robotic precision and\nsafety, expand access to minimally invasive therapy, and enhance the\nproductivity, connectivity, and intelligence in the operating room.\nStereotaxis technology has been used to treat over 150,000 patients across the\nUnited States, Europe, Asia, and elsewhere. For more information, please visit\nwww.Stereotaxis.com.\n\nThis press release includes statements that may constitute\n“forward-looking” statements, usually containing the words “believe”,\n“estimate”, “project”, “expect” or similar expressions. These\nforward-looking statements include without limitation statements regarding the\nrecently completed acquisition of Robocath, including the Company’s ability\nto advance its strategy, integrate Robocath, and grow revenue significantly\nwithout having to subject investors to substantial dilution. Forward-looking\nstatements inherently involve risks and uncertainties that could cause actual\nresults to differ materially. Factors that would cause or contribute to such\ndifferences include, but are not limited to, uncertainties involving the\nfollowing: the Company’s ability to manage expenses at sustainable levels;\nacceptance of the Company’s products in the marketplace; the effect of\nglobal economic conditions, including tariffs, on the ability and willingness\nof customers to purchase its technology; competitive factors; changes\nresulting from healthcare policy; dependence upon third-party vendors; timing\nof regulatory approvals, including as it relates to Robocath’s products; the\nimpact of pandemics or other disasters; statements generally relating to our\nrecent acquisition of Robocath, including any benefits expected from the\nacquisitions, as well as any plans, forecasts and other expectations with\nrespect to Robocath’s business following the completion of the transaction;\nand the other risks discussed in the Company's periodic and other filings with\nthe Securities and Exchange Commission.\n\nBy making these forward-looking statements, the Company undertakes no\nobligation to update these statements for revisions or changes after the date\nof this release. Additional information will also be set forth in future\nfilings that we make with the SEC from time to time. All forward-looking\nstatements in this press release are based on information available to us as\nof the date hereof, and we do not assume any obligation to update the\nforward-looking statements provided to reflect events that occur or\ncircumstances that exist after the date on which they were made. There can be\nno assurance that the Company will recognize revenue related to its purchase\norders and other commitments because some of these purchase orders and other\ncommitments are subject to contingencies that are outside of the Company's\ncontrol and may be revised, modified, delayed, or canceled.\n\nCompany\nContacts:                                                        \nDavid L. Fischel\nChairman and Chief Executive Officer\n\nKimberly R.\nPeery                                                        \nChief Financial Officer\n\n314-678-6100\nInvestors@Stereotaxis.com\n\n\n\n Stereotaxis, Inc.                                                                                                                                                                                    \n CONSOLIDATED STATEMENTS OF OPERATIONS                                                                                                                                                                \n (Unaudited)                                                                                                                                                                                          \n                                                                                                                                                                                                      \n (in thousands, except share and per share amounts)         Three Months Ended June 30,                                           Six Months Ended June 30,                                           \n                                                                 2026                        2025                                 2026                                     2025                       \n                                                                                                                                                                                                      \n Revenue:                                                                                                                                                                                             \n Systems                                                    $    1,479                       $    3,038                           $    2,798                          $    5,002                      \n Disposables, service and accessories                            6,191                            5,760                                11,163                              11,268                     \n Total revenue                                                   7,670                            8,798                                13,961                              16,270                     \n                                                                                                                                                                                                      \n Cost of revenue:                                                                                                                                                                                     \n Systems                                                         1,057                            2,366                                1,861                               4,033                      \n Disposables, service and accessories                            2,127                            1,853                                3,820                               3,594                      \n Total cost of revenue                                           3,184                            4,219                                5,681                               7,627                      \n                                                                                                                                                                                                      \n Gross margin                                                    4,486                            4,579                                8,280                               8,643                      \n                                                                                                                                                                                                      \n Operating expenses:                                                                                                                                                                                  \n Research and development                                        2,390                            1,777                                4,787                               4,127                      \n Sales and marketing                                             2,595                            3,269                                5,212                               6,417                      \n General and administrative                                      4,069                            4,002                                8,830                               8,497                      \n Other                                                           -                                (492                     )           -                                   (492                )      \n Total operating expenses                                        9,054                            8,556                                18,829                              18,549                     \n Operating loss                                                  (4,568       )                   (3,977                   )           (10,549         )                   (9,906              )      \n                                                                                                                                                                                                      \n Other income                                                    -                                (1                       )           (5              )                   (1                  )      \n Interest income, net                                            100                              152                                  225                                 258                        \n Net loss                                                   $    (4,468       )              $    (3,826                   )      $    (10,329         )              $    (9,649              )      \n Cumulative dividend on convertible preferred stock              (314         )                   (318                     )           (625            )                   (632                )      \n Net loss attributable to common stockholders               $    (4,782       )              $    (4,144                   )      $    (10,954         )              $    (10,281             )      \n                                                                                                                                                                                                      \n Net loss per share attributed to common stockholders:                                                                                                                                                \n Basic                                                      $    (0.05        )              $    (0.05                    )      $    (0.11           )              $    (0.12               )      \n                                                                                                                                                                                                      \n Diluted                                                    $    (0.05        )              $    (0.05                    )      $    (0.11           )              $    (0.12               )      \n                                                                                                                                                                                                      \n Weighted average number of common shares and equivalents:                                                                                                                                            \n Basic                                                           100,031,760                      87,952,086                           99,496,942                          87,861,231                 \n                                                                                                                                                                                                      \n Diluted                                                         100,031,760                      87,952,086                           99,496,942                          87,861,231                 \n                                                                                                                                                                                                      \n\n\n\n STEREOTAXIS, INC.                                                                                                                                                                                               \n CONSOLIDATED BALANCE SHEETS                                                                                                                                                                                     \n                                                                                                                                                                                                                 \n                                                                                                                                                                                                                 \n (in thousands, except share amounts)                                                                                                                        June 30, 2026             December 31, 2025         \n                                                                                                                                                             (Unaudited)                                         \n Assets                                                                                                                                                                                                          \n Current assets:                                                                                                                                                                                                 \n Cash and cash equivalents                                                                                                                                   $      10,491             $       13,421            \n Accounts receivable, net of allowance of $594 and $541 at 2026 and 2025, respectively                                                                              7,549                      5,847             \n Insurance receivable                                                                                                                                               6,316                      4,316             \n Inventories, net                                                                                                                                                   12,520                     9,567             \n Prepaid expenses and other current assets                                                                                                                          1,111                      698               \n Total current assets                                                                                                                                               37,987                     33,849            \n Property and equipment, net                                                                                                                                        2,881                      3,019             \n Goodwill                                                                                                                                                           3,764                      3,764             \n Intangible assets, net                                                                                                                                             5,957                      6,429             \n Operating lease right-of-use assets                                                                                                                                4,658                      4,912             \n Prepaid and other non-current assets                                                                                                                               335                        278               \n Total assets                                                                                                                                                $      55,582             $       52,251            \n                                                                                                                                                                                                                 \n Liabilities and stockholders' equity                                                                                                                                                                            \n Current liabilities:                                                                                                                                                                                            \n Accounts payable                                                                                                                                            $      6,866              $       4,768             \n Accrued liabilities                                                                                                                                                1,325                      2,065             \n Accrued legal liabilities                                                                                                                                          6,316                      4,316             \n Deferred revenue                                                                                                                                                   5,928                      5,675             \n Current contingent consideration                                                                                                                                   5,673                      4,894             \n Current portion of operating lease liabilities                                                                                                                     689                        642               \n Total current liabilities                                                                                                                                          26,797                     22,360            \n Long-term deferred revenue                                                                                                                                         384                        555               \n Long-term contingent consideration                                                                                                                                 5,343                      4,724             \n Operating lease liabilities                                                                                                                                        4,484                      4,794             \n Other liabilities                                                                                                                                                  1,097                      1,097             \n Total liabilities                                                                                                                                                  38,105                     33,530            \n                                                                                                                                                                                                                 \n Series A - Convertible preferred stock:                                                                                                                                                                         \n Convertible preferred stock, Series A, par value $0.001; 10,000,000 shares authorized, 20,983 and 21,008 shares outstanding at 2026 and 2025, respectively         5,234                      5,240             \n Stockholders' equity:                                                                                                                                                                                           \n Common stock, par value $0.001; 300,000,000 shares authorized, 97,938,091 and 95,339,628 shares issued at 2026 and 2025, respectively                              98                         95                \n Additional paid-in capital                                                                                                                                         606,048                    596,960           \n Treasury stock, 4,015 shares at 2026 and 2025                                                                                                                      (206      )                (206      )       \n Accumulated deficit                                                                                                                                                (593,697  )                (583,368  )       \n Total stockholders' equity                                                                                                                                         12,243                     13,481            \n Total liabilities and stockholders' equity                                                                                                                  $      55,582             $       52,251            \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/95a5b8ca-b7c0-4c80-8ca7-063ef10706c3)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1lYNCD","title":"Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates","author":"Globe Newswire","ticker":"STXS","created":"2026-08-11T20:01:00.110Z","tickers":["STXS"],"exchange":"NYSE American","article_body":"* Robotic catheter revenue surpasses $1M in the quarter, growing 270%\nsequentially\n* First GenesisX robotic system purchase by US hospital to be installed this\nfall\n* Multiple Synchrony digital operating room systems sold and installed\nfollowing FDA clearance in April\n* Completed previously announced acquisition of Robocath, strengthening\nrobotic technology leadership across the full spectrum of endovascular\nprocedures\nST. LOUIS, Mo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stereotaxis\n(https://www.globenewswire.com/Tracker?data=gcMmZUXDGD1yUqVYZTVnNNZHfPAG_2Kaa_we2f8BLBbjgB0UWZYBVBS2UHTTqbmuC8yZkbDPHnBIRFfNodUWgqQ_ZSVCLHlAGqESf1jY-mY=)\n(NYSE: STXS), a pioneer and global leader in surgical robotics for minimally\ninvasive endovascular intervention, today reported business updates and\nfinancial results for the second quarter ended June 30, 2026.\n\n“Stereotaxis has reached an important commercial inflection point. Following\nyears of product development and regulatory milestones, the Company’s\nexpanded robotic platform is now generating accelerating commercial adoption\nacross multiple product lines,” said David Fischel, Stereotaxis Chairman and\nCEO. “Over the last several years we advanced an exciting ecosystem of\nrobotic, catheter and digital innovations through development and regulatory\nmilestones. We are now witnessing the initial green shoots of commercial\nsuccess, including quarterly revenue from our novel robotic catheters\nexceeding one million dollars, the first Synchrony system sales, and the first\nUS purchase of a GenesisX robot.”\n\n“We are making methodical progress on the operational and commercial efforts\nneeded to drive revenue growth. We expect continued momentum throughout this\nyear as we ramp manufacturing and address commercial friction. We have line of\nsight to sustained revenue growth and reaching cash flow profitability in the\ncoming quarters.”\n\n“In parallel to our commercial efforts, we continue to invest in a broad\npipeline of innovations that expand our technology into a platform across\nendovascular surgery, enhances our competitiveness in electrophysiology, and\ndelivers digital connectivity, automation and intelligence to the operating\nroom.”\n\n2026 Second Quarter Financial Results\nRevenue for the second quarter of 2026 totaled $7.7 million. System revenue of\n$1.5 million declined from $3.0 million in the prior year second quarter, with\nthe lack of a robotic system delivery in the quarter partially countered by\ninitial Synchrony sales. Recurring revenue of $6.2 million increased from $5.8\nmillion in the prior year second quarter, reflecting contributions from\nStereotaxis’ new robotic catheters counteracting general procedural pressure\nfrom limited catheter supply.\n\nGross margin for the second quarter of 2026 was 58% of revenue. Recurring\nrevenue gross margin was 66%, and system gross margin was 29%. Operating\nexpenses in the quarter of $9.1 million included $2.5 million in non-cash\ncharges for stock compensation expense, mark-to-market adjustment for\nacquisition related contingent earnout consideration, and amortization of\nacquired intangible assets. Excluding these non-cash charges, adjusted\noperating expenses were $6.6 million, consistent with the year-ago period when\nadjusting for a one-time employee retention tax credit received in the prior\nyear.\n\nOperating loss and net loss in the second quarter of 2026 were ($4.6) million\nand ($4.5) million, respectively, compared with ($4.0) million and ($3.8)\nmillion in the previous year. Adjusted operating loss and adjusted net loss\nfor the quarter, excluding non-cash charges, were ($2.1) million and ($2.0)\nmillion, respectively, compared with ($1.4) million and ($1.3) million in the\nprevious year quarter. Negative free cash flow for the second quarter was\n($3.7) million, consistent with the previous year.\n\nCash Balance and Liquidity\nAt June 30, 2026, Stereotaxis had cash and cash equivalents of $10.5 million\nand no debt.\n\nForward Looking Expectations\nStereotaxis anticipates recurring revenue to grow to approximately $7 million\nin the third quarter and $8 million in the fourth quarter of this year, driven\nby methodical increases in MAGiC catheter manufacturing. System revenue is\nexpected to be approximately $3 million in each of the third and fourth\nquarters.\n\nStereotaxis believes it can advance its strategy, integrate Robocath, and grow\nrevenue significantly without having to subject investors to substantial\ndilution. Cash flow profitability is anticipated to be reached in the first\nhalf of 2027.\n\nConference Call and Webcast\nStereotaxis will host a conference call and webcast today, August 11, 2026, at\n4:30 p.m. Eastern Time. To access the conference call, dial 800-715-9871 (US\nand Canada) or 646-307-1963 (International) and give the participant pass code\n4404741. To access the live and replay webcast, please visit the investor\nrelations section of the Stereotaxis website at www.Stereotaxis.com.\n\nAbout Stereotaxis\nStereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical\nrobotics for minimally invasive endovascular intervention. Its mission is the\ndiscovery, development and delivery of robotic systems, instruments, and\ninformation solutions for the interventional laboratory. These innovations\nhelp physicians provide unsurpassed patient care with robotic precision and\nsafety, expand access to minimally invasive therapy, and enhance the\nproductivity, connectivity, and intelligence in the operating room.\nStereotaxis technology has been used to treat over 150,000 patients across the\nUnited States, Europe, Asia, and elsewhere. For more information, please visit\nwww.Stereotaxis.com.\n\nThis press release includes statements that may constitute\n“forward-looking” statements, usually containing the words “believe”,\n“estimate”, “project”, “expect” or similar expressions. These\nforward-looking statements include without limitation statements regarding the\nrecently completed acquisition of Robocath, including the Company’s ability\nto advance its strategy, integrate Robocath, and grow revenue significantly\nwithout having to subject investors to substantial dilution. Forward-looking\nstatements inherently involve risks and uncertainties that could cause actual\nresults to differ materially. Factors that would cause or contribute to such\ndifferences include, but are not limited to, uncertainties involving the\nfollowing: the Company’s ability to manage expenses at sustainable levels;\nacceptance of the Company’s products in the marketplace; the effect of\nglobal economic conditions, including tariffs, on the ability and willingness\nof customers to purchase its technology; competitive factors; changes\nresulting from healthcare policy; dependence upon third-party vendors; timing\nof regulatory approvals, including as it relates to Robocath’s products; the\nimpact of pandemics or other disasters; statements generally relating to our\nrecent acquisition of Robocath, including any benefits expected from the\nacquisitions, as well as any plans, forecasts and other expectations with\nrespect to Robocath’s business following the completion of the transaction;\nand the other risks discussed in the Company's periodic and other filings with\nthe Securities and Exchange Commission.\n\nBy making these forward-looking statements, the Company undertakes no\nobligation to update these statements for revisions or changes after the date\nof this release. Additional information will also be set forth in future\nfilings that we make with the SEC from time to time. All forward-looking\nstatements in this press release are based on information available to us as\nof the date hereof, and we do not assume any obligation to update the\nforward-looking statements provided to reflect events that occur or\ncircumstances that exist after the date on which they were made. There can be\nno assurance that the Company will recognize revenue related to its purchase\norders and other commitments because some of these purchase orders and other\ncommitments are subject to contingencies that are outside of the Company's\ncontrol and may be revised, modified, delayed, or canceled.\n\nCompany\nContacts:                                                        \nDavid L. Fischel\nChairman and Chief Executive Officer\n\nKimberly R.\nPeery                                                        \nChief Financial Officer\n\n314-678-6100\nInvestors@Stereotaxis.com\n\n\n\n Stereotaxis, Inc.                                                                                                                                                                                    \n CONSOLIDATED STATEMENTS OF OPERATIONS                                                                                                                                                                \n (Unaudited)                                                                                                                                                                                          \n                                                                                                                                                                                                      \n (in thousands, except share and per share amounts)         Three Months Ended June 30,                                           Six Months Ended June 30,                                           \n                                                                 2026                        2025                                 2026                                     2025                       \n                                                                                                                                                                                                      \n Revenue:                                                                                                                                                                                             \n Systems                                                    $    1,479                       $    3,038                           $    2,798                          $    5,002                      \n Disposables, service and accessories                            6,191                            5,760                                11,163                              11,268                     \n Total revenue                                                   7,670                            8,798                                13,961                              16,270                     \n                                                                                                                                                                                                      \n Cost of revenue:                                                                                                                                                                                     \n Systems                                                         1,057                            2,366                                1,861                               4,033                      \n Disposables, service and accessories                            2,127                            1,853                                3,820                               3,594                      \n Total cost of revenue                                           3,184                            4,219                                5,681                               7,627                      \n                                                                                                                                                                                                      \n Gross margin                                                    4,486                            4,579                                8,280                               8,643                      \n                                                                                                                                                                                                      \n Operating expenses:                                                                                                                                                                                  \n Research and development                                        2,390                            1,777                                4,787                               4,127                      \n Sales and marketing                                             2,595                            3,269                                5,212                               6,417                      \n General and administrative                                      4,069                            4,002                                8,830                               8,497                      \n Other                                                           -                                (492                     )           -                                   (492                )      \n Total operating expenses                                        9,054                            8,556                                18,829                              18,549                     \n Operating loss                                                  (4,568       )                   (3,977                   )           (10,549         )                   (9,906              )      \n                                                                                                                                                                                                      \n Other income                                                    -                                (1                       )           (5              )                   (1                  )      \n Interest income, net                                            100                              152                                  225                                 258                        \n Net loss                                                   $    (4,468       )              $    (3,826                   )      $    (10,329         )              $    (9,649              )      \n Cumulative dividend on convertible preferred stock              (314         )                   (318                     )           (625            )                   (632                )      \n Net loss attributable to common stockholders               $    (4,782       )              $    (4,144                   )      $    (10,954         )              $    (10,281             )      \n                                                                                                                                                                                                      \n Net loss per share attributed to common stockholders:                                                                                                                                                \n Basic                                                      $    (0.05        )              $    (0.05                    )      $    (0.11           )              $    (0.12               )      \n                                                                                                                                                                                                      \n Diluted                                                    $    (0.05        )              $    (0.05                    )      $    (0.11           )              $    (0.12               )      \n                                                                                                                                                                                                      \n Weighted average number of common shares and equivalents:                                                                                                                                            \n Basic                                                           100,031,760                      87,952,086                           99,496,942                          87,861,231                 \n                                                                                                                                                                                                      \n Diluted                                                         100,031,760                      87,952,086                           99,496,942                          87,861,231                 \n                                                                                                                                                                                                      \n\n\n\n STEREOTAXIS, INC.                                                                                                                                                                                               \n CONSOLIDATED BALANCE SHEETS                                                                                                                                                                                     \n                                                                                                                                                                                                                 \n                                                                                                                                                                                                                 \n (in thousands, except share amounts)                                                                                                                        June 30, 2026             December 31, 2025         \n                                                                                                                                                             (Unaudited)                                         \n Assets                                                                                                                                                                                                          \n Current assets:                                                                                                                                                                                                 \n Cash and cash equivalents                                                                                                                                   $      10,491             $       13,421            \n Accounts receivable, net of allowance of $594 and $541 at 2026 and 2025, respectively                                                                              7,549                      5,847             \n Insurance receivable                                                                                                                                               6,316                      4,316             \n Inventories, net                                                                                                                                                   12,520                     9,567             \n Prepaid expenses and other current assets                                                                                                                          1,111                      698               \n Total current assets                                                                                                                                               37,987                     33,849            \n Property and equipment, net                                                                                                                                        2,881                      3,019             \n Goodwill                                                                                                                                                           3,764                      3,764             \n Intangible assets, net                                                                                                                                             5,957                      6,429             \n Operating lease right-of-use assets                                                                                                                                4,658                      4,912             \n Prepaid and other non-current assets                                                                                                                               335                        278               \n Total assets                                                                                                                                                $      55,582             $       52,251            \n                                                                                                                                                                                                                 \n Liabilities and stockholders' equity                                                                                                                                                                            \n Current liabilities:                                                                                                                                                                                            \n Accounts payable                                                                                                                                            $      6,866              $       4,768             \n Accrued liabilities                                                                                                                                                1,325                      2,065             \n Accrued legal liabilities                                                                                                                                          6,316                      4,316             \n Deferred revenue                                                                                                                                                   5,928                      5,675             \n Current contingent consideration                                                                                                                                   5,673                      4,894             \n Current portion of operating lease liabilities                                                                                                                     689                        642               \n Total current liabilities                                                                                                                                          26,797                     22,360            \n Long-term deferred revenue                                                                                                                                         384                        555               \n Long-term contingent consideration                                                                                                                                 5,343                      4,724             \n Operating lease liabilities                                                                                                                                        4,484                      4,794             \n Other liabilities                                                                                                                                                  1,097                      1,097             \n Total liabilities                                                                                                                                                  38,105                     33,530            \n                                                                                                                                                                                                                 \n Series A - Convertible preferred stock:                                                                                                                                                                         \n Convertible preferred stock, Series A, par value $0.001; 10,000,000 shares authorized, 20,983 and 21,008 shares outstanding at 2026 and 2025, respectively         5,234                      5,240             \n Stockholders' equity:                                                                                                                                                                                           \n Common stock, par value $0.001; 300,000,000 shares authorized, 97,938,091 and 95,339,628 shares issued at 2026 and 2025, respectively                              98                         95                \n Additional paid-in capital                                                                                                                                         606,048                    596,960           \n Treasury stock, 4,015 shares at 2026 and 2025                                                                                                                      (206      )                (206      )       \n Accumulated deficit                                                                                                                                                (593,697  )                (583,368  )       \n Total stockholders' equity                                                                                                                                         12,243                     13,481            \n Total liabilities and stockholders' equity                                                                                                                  $      55,582             $       52,251            \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/95a5b8ca-b7c0-4c80-8ca7-063ef10706c3)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-11T20:01:00.192652979Z","server_sent_at_ms":1786478460192},"received_at":"2026-08-11T20:01:00.591Z","source_url":"https://www.globenewswire.com/news-release/2026/08/11/3343137/21634/en/stereotaxis-reports-2026-second-quarter-financial-results-business-updates.html"},"analysis":{"id":"104920","press_release_id":"115916","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["Total revenue declined year-over-year","GAAP net loss widened to $4.5 million from $3.8 million in the prior year","Cash balance of $10.5 million with negative free cash flow of $3.7 million in the quarter raises solvency concerns if targets are missed"],"eventType":"earnings","narrative":"Stereotaxis reported Q2 revenue of $7.7 million, a decrease from the prior year, as system revenue dropped to $1.5 million while recurring revenue increased to $6.2 million.\n\nThe company highlighted a commercial inflection point with robotic catheter revenue surpassing $1 million, up 270% sequentially, alongside the first US purchase of a GenesisX system and sales of Synchrony systems.\n\nManagement guided for recurring revenue growth to approximately $7 million in Q3 and $8 million in Q4, anticipating cash flow profitability in the first half of 2027 while ending the quarter with $10.5 million in cash and no debt.","sentiment":"mixed","agentHooks":{"shouldPost":false,"suggestedAngle":"Mixed earnings show revenue decline but strong catheter growth and path to profitability."},"keyFigures":{"revenue":"$7.7 million","guidance":"Q3 recurring revenue ~$7M, Q4 recurring revenue ~$8M, Q3/Q4 system revenue ~$3M each","customDimensions":{"net_loss":"$4.5 million","cash_balance":"$10.5 million","gross_margin":"58%","operating_loss":"$4.6 million","system_revenue":"$1.5 million","catheter_revenue":">$1M","adjusted_net_loss":"$2.0 million","recurring_revenue":"$6.2 million"}},"quotedText":"Stereotaxis has reached an important commercial inflection point. Following years of product development and regulatory milestones, the Company’s expanded robotic platform is now generating accelerating commercial adoption across multiple product lines.","namedEntities":{"people":[{"name":"David Fischel","role":"Chairman and CEO"},{"name":"Kimberly R. Peery","role":"CFO"}],"products":["GenesisX","Synchrony","MAGiC"],"companies":[{"name":"Stereotaxis","ticker":"STXS"},{"name":"Robocath","relationship":"acquired company"}],"dollarAmounts":[{"amount":"$7.7 million","context":"Q2 2026 total revenue"},{"amount":"$1.5 million","context":"Q2 2026 system revenue"},{"amount":"$3.0 million","context":"Q2 2025 system revenue"},{"amount":"$6.2 million","context":"Q2 2026 recurring revenue"},{"amount":"$5.8 million","context":"Q2 2025 recurring revenue"},{"amount":"$10.5 million","context":"cash and cash equivalents at June 30, 2026"}]},"materialImpact":{"score":3,"reasoning":"Earnings release showing mixed financial performance with total revenue declining year-over-year but recurring revenue growing. Management highlights a commercial inflection point and provides guidance for revenue growth and cash flow profitability in 2027, mitigating concerns over widening GAAP losses."},"tickerRelevance":{"others":[],"primary":"STXS"},"globalImportance":15,"audienceRelevance":20,"eventTypeSecondary":["guidance_update"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"earnings_mixed_results","sectorWeight":"health_care_equipment"}},"event_type":"earnings","event_type_secondary":["guidance_update"],"sentiment":"mixed","material_impact_score":3,"narrative":"Stereotaxis reported Q2 revenue of $7.7 million, a decrease from the prior year, as system revenue dropped to $1.5 million while recurring revenue increased to $6.2 million.\n\nThe company highlighted a commercial inflection point with robotic catheter revenue surpassing $1 million, up 270% sequentially, alongside the first US purchase of a GenesisX system and sales of Synchrony systems.\n\nManagement guided for recurring revenue growth to approximately $7 million in Q3 and $8 million in Q4, anticipating cash flow profitability in the first half of 2027 while ending the quarter with $10.5 million in cash and no debt.","key_figures":{"revenue":"$7.7 million","guidance":"Q3 recurring revenue ~$7M, Q4 recurring revenue ~$8M, Q3/Q4 system revenue ~$3M each","customDimensions":{"net_loss":"$4.5 million","cash_balance":"$10.5 million","gross_margin":"58%","operating_loss":"$4.6 million","system_revenue":"$1.5 million","catheter_revenue":">$1M","adjusted_net_loss":"$2.0 million","recurring_revenue":"$6.2 million"}},"named_entities":{"people":[{"name":"David Fischel","role":"Chairman and CEO"},{"name":"Kimberly R. Peery","role":"CFO"}],"products":["GenesisX","Synchrony","MAGiC"],"companies":[{"name":"Stereotaxis","ticker":"STXS"},{"name":"Robocath","relationship":"acquired company"}],"dollarAmounts":[{"amount":"$7.7 million","context":"Q2 2026 total revenue"},{"amount":"$1.5 million","context":"Q2 2026 system revenue"},{"amount":"$3.0 million","context":"Q2 2025 system revenue"},{"amount":"$6.2 million","context":"Q2 2026 recurring revenue"},{"amount":"$5.8 million","context":"Q2 2025 recurring revenue"},{"amount":"$10.5 million","context":"cash and cash equivalents at June 30, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-11T22:20:07.410Z","global_importance":15,"audience_relevance":20,"importance_components":{"tickerTier":"micro-cap","eventGravity":"earnings_mixed_results","sectorWeight":"health_care_equipment"}},"durationMs":227173,"modelName":"glm-4.7"}}